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Streptococcus  agalactiae  (group  B streptococcus  (GBS))  is the  leading  cause  of  neonatal  sepsis  and  menin-
gitis in  many  countries.  Intrapartum  antibiotic  strategies  have  reduced  the  incidence  of early-onset
neonatal  GBS  in a number  of countries  but have  had  no impact  on late  onset  GBS infection  (LOD).  In
low/middle  income  settings,  the disease  burden  remains  uncertain  although  in  several  countries  of  South-
ern Africa  appears  comparable  to or higher  than  that of  high-income  countries.  As disease  may  be rapidly
fulminating  cases  can  be missed  before  appropriate  samples  are  obtained  and  this  may  lead  to underes-onjugate
roup B streptococcus
timation  of  the  true  burden.  Given  the  rapid onset  and  progression  within  hours  of birth  as  well  as  the
deﬁciencies  in  IAP  strategies  and  absence  of  a solution  for  preventing  LOD,  it is  clear  that  administration
of  a suitable  vaccine  in  pregnancy  could  provide  a better  solution  in all settings;  it should  also  be  cost
effective.  The  current  leading  vaccine  candidates  are  CPS-protein  conjugate  vaccines  but protein-based
vaccines  are  also  in  development  and  one  has  recently  commenced  clinical  trials.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC. About the disease and pathogen
Streptococcus agalactiae (group B streptococcus (GBS)) remains
he leading cause of neonatal sepsis and meningitis in many
ountries and an important cause of disease in pregnant women,
mmunocompromised adults and the elderly. The highest incidence
f all is in the ﬁrst 3 months of life and this review will focus on this
roup.
Intrapartum antibiotic (IAP) strategies have reduced the inci-
ence of early-onset neonatal GBS (EOD, deﬁned as disease
ccurring <7 days of age) where applied, but have had no impact
n late onset GBS infection (LOD, 7–90 days of age) and only
 limited impact on disease in pregnant women [1]. In low
nd middle-income country (LMIC) settings, the disease burden
emains uncertain although in several countries of Southern Africa
ppears comparable to or higher than that of high-income countries
HIC) [2,3]. EOD may  be rapidly fulminating and cases can there-
ore be missed before appropriate samples are obtained. This may
ead to signiﬁcant underestimation of the true burden and be a par-
icular issue in many African and Asian countries; comprehensive
pidemiological data from such countries are urgently required [4].
 recent meta-analysis emphasized this and reported an overall
stimate of GBS incidence of 0.53 per 1000 live births and a mean
∗ Tel.: +44 20 87255980.
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264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceBY  license  (http://creativecommons.org/licenses/by/3.0/).
case fatality ratio of 9.6% (95% CI 7.5–11.8). In African infants the
incidence was  1.21 per 1000 live births, with a case fatality of 22%
[5].
EOD accounts for approximately 60–70% of all neonatal GBS
disease. There are 10 GBS serotypes and ST Ia, II, III and V are respon-
sible for most EOD. Maternal carriage of GBS in the gastrointestinal
and/or genital tracts is a pre-requisite for EOD, vertical transmis-
sion occurring during or just prior to birth. An estimated 20–30%
of pregnant women are colonized with GBS (data derived mostly
from HIC [6,7]) and approximately 50% of their babies become col-
onized and 1% of these babies progress to develop invasive disease.
Disease may  occur rapidly; signs are evident at birth or within 12 h
in over 90% of cases and presentation is typically with pneumonia
or sepsis [8].
Two major strategies for targeting women  to receive IAP are
used: risk factor based (RFB) or swab culture-based. The former
is based on the presence of any of the following intrapartum risk
factors: delivery at <37 weeks’ gestation, intrapartum fever, or rup-
ture of membranes for ≥18 h; while the latter is based on a positive
vaginal-rectal swab, typically obtained at 35–37 weeks gestation
and cultured for GBS using selective media. For both strategies IAP
is also recommended for women with GBS bacteriuria at any time
during their current pregnancy or for women who have had a pre-
vious baby with EOD [9]. A potential alternative strategy is based
on detection of GBS using real time PCR methodology from swabs
obtained in labour [7]. This method has the obvious advantage
of detecting GBS at the most relevant time for IAP, as screening
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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arlier in pregnancy (e.g. 35–37 weeks) can result in both false
ositive and false negative results.
A number of issues arise with this mode of prevention, includ-
ng its feasibility in LMIC. In HIC there are issues with compliance,
ost and feasibility (especially of PCR in labour) and more theoret-
cal concerns about the excessive use of antibiotics. Of particular
mportance is that IAP does not decrease LOD. LOD is caused pre-
ominantly by serotype III, is acquired perinatally, nosocomially
r from community sources, and in up to 50% of cases presents
ith meningitis, which is associated with signiﬁcant mortality and
ong-term morbidity [10,11].
Given the rapid onset and progression of EOD within hours of
irth as well as the deﬁciencies in IAP strategies and absence of
 solution for preventing LOD, it is clear that administration of a
uitable vaccine in pregnancy could provide a better solution in
ll settings; it should also be cost effective. A recently published
ecision-analytic model based on South African data compared four
trategies: no intervention, maternal GBS vaccination, RFB-IAP, and
accination plus RFB-IAP. GBS vaccination alone was  predicted to
revent 30–54% of infant GBS cases compared to no intervention.
or vaccine prices between $10 and $30, and mid-range efﬁcacy,
ts cost ranged from $676 to $2390 per disability-adjusted life-year
DALY) averted ($US 2010), compared to no intervention. RFB-IAP
lone, compared to doing nothing, prevented 10% of infant GBS
ases at a cost of $240/DALY. Vaccine plus RFB-IAP prevented 48%
f cases at a cost of $664–2128/DALY. It was concluded that vacci-
ation would substantially reduce the burden of infant GBS disease
n South Africa and would be very cost-effective by WHO  guidelines
12] (Table 1).
There is also evidence that GBS may  contribute to prematu-
ity, birth asphyxia and stillbirths; for example, a recent systematic
eview estimated it might account for up to 12% of stillbirths [13].
hese are important consequences but are difﬁcult to quantify.
. Overview of current efforts
.1. EITHER vaccines currently available and their limitations OR
iological feasibility for vaccine development
In the 1930s, Rebecca Lanceﬁeld demonstrated that protection
gainst GBS infection in mice could be achieved using capsular
olysaccharide (CPS)-speciﬁc rabbit sera [14]. CPS remains the
est-studied target of GBS, and until recently was  the only target
or which human vaccine trials have been undertaken. In the 1980s,
uman trials with plain capsular carbohydrate based vaccines
emonstrated that they were well tolerated, including in pregnancy
15], but only modestly immunogenic. GBS polysaccharide-protein
onjugate vaccines (predominantly using tetanus toxoid as the
onjugate protein) were then developed and have subsequently
een administered to healthy adults and pregnant women  [16–19].
ssentially all of these clinical vaccine studies were coordinated by
 key group of investigators in the USA with funding and sponsor-
hip through the National Institutes of Health and National Institute
f Allergy and Infectious Diseases. Multiple studies were under-
aken but progress slowed as no vaccine manufacturer appeared
illing to progress this candidate to large-scale development, in
arge part due to perceived issues with the feasibility of maternal
mmunization.
More recently, a vaccine manufacturer (Novartis, now GSK) has
eveloped and commenced clinical trials with a new CPS conjugate
accine, based on CRM197 as the conjugate protein. Randomized
linical trials to evaluate the safety and immunogenicity of vacci-
ation during pregnancy are underway; some have been reported
s conference abstracts and some results are available on clinical-
rials.gov (NCT01193920, NCT01446289, NCT02046148).2016) 2876–2879 2877
Another manufacturer (MinervaX) has recently commenced
phase 1 clinical trials with a protein vaccine (GBS-NN), made from
the N-terminal domains of the Rib and AlphaC surface proteins of
GBS (NCT02459262).
Additionally and most signiﬁcantly, the attitude of healthcare
workers, the general public, regulators and policy makers towards
vaccination during pregnancy has changed. This is exempliﬁed
by the World Health Organization’s global recommendations on
inﬂuenza vaccine in pregnant women  [20], multiple countries’ rec-
ommendations on pertussis vaccine in pregnant women  and, in
the UK, by the high coverage achieved with a pertussis-containing
vaccine in pregnancy [21].
2.2. General approaches to vaccine development for this disease
for low and middle income country
The leading indication for GBS vaccines is the prevention of
neonatal GBS infections (up to 2–3 months of age), including
meningitis. Disease occurs too early in life for neonates or infants
to mount an effective immune response following vaccination:
the majority of infants with GBS disease present on day 1 of life.
Therefore, the obvious target for vaccination is pregnant women.
Pre-pregnancy or adolescent vaccination may  also be considered,
but are less feasible, especially in LMIC settings where there is no
current platform for vaccination in these groups. The only alterna-
tive for prevention of EOD (but not LOD) is IAP, but it is generally
believed to be too difﬁcult to implement this in LMICs for logistical
reasons. Additionally, evidence from cohort studies suggests that
IAP based on swab-based screening at 35–37 weeks is a superior
strategy to that based on risk factors [22]; however swab-based
screening is signiﬁcantly more expensive. The South African cost-
effectiveness data suggested that GBS vaccination might prevent
30–54% of infant GBS cases while RFB-IAP might prevent only 10%
of infant GBS cases [12].
3. Technical and regulatory assessment
The current leading vaccine candidates are capsular
polysaccharide-protein conjugate vaccines. Multiple clinical
studies have already been completed in order to assess the
optimal dosage, schedule, requirement for adjuvant, and the
persistence of response, as well as immunogenicity and safety
trials in pregnant women. These candidates have so far used
conventional carrier proteins (tetanus toxoid, CRM197) [17]
(clinicaltrials.gov: NCT01193920). The developmental pathway
for conjugate vaccines using such proteins is now well established
(e.g. Hib/meningococcal/pneumococcal conjugate vaccines).
A major regulatory issue for this vaccine is that it is being devel-
oped speciﬁcally for use in pregnant women. This is a new paradigm
for regulators as currently no vaccine is licensed speciﬁcally for
this use. The approach taken for a GBS vaccine and the experi-
ence gained will have implications for other vaccines also being
developed speciﬁcally for pregnancy (e.g. RSV).
Another signiﬁcant consideration in the development pathway
for this vaccine is whether licensure will require large scale ran-
domized placebo controlled trials that demonstrate efﬁcacy against
clinical disease, or whether regulatory approval can be based on
demonstration of achievement of serological correlates of protec-
tion. The latter approach was  taken for licensure of meningococcal
C [23] and meningococcal B vaccines. Recent guidance lays the
groundwork for such an approach for vaccines developed for preg-
nancy [24].
Serological correlates of protection. Baker and colleagues initially
characterized the association between serotype-speciﬁc CPS anti-
body levels and invasive GBS disease in newborns in 1976 [25].
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Table 1
Development status of current vaccine candidates (POC, proof of concept trial).
Developer Candidate name/identiﬁer Preclinical Phase I Phase II POC Phase III
NIH Tetanus toxoid-CPS conjugates:
monovalent (multiple studies),
bivalent (one study); CRM197–CPS
conjugate: monovalent (one study)
x x x x (trial in pregnant
women)
Novartis/GSK CRM197-CPS conjugates: monovalent
(multiple), trivalent (several)
x x x x (trial in pregnant
women)
Minervax N-terminal domains of the Rib and
AlphaC surface proteins
x x
x
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Various academic groups Other protein(s) and/or protein-CPS
conjugates
n the majority of subsequent studies lower antibody levels have
een found in infants with EOD and LOD, compared with infants
ho were exposed to mothers colonized with the same ST, but
ho did not develop disease. Different speciﬁc levels have been
eﬁned in different studies. For example, in a meta-analysis, the
dds of invasive GBS disease were 6.56 (95% CI: 2.10–20.55) and
.38 (95% CI: 1.20–4.70) times greater in infants whose mothers had
ntibody levels <2 g/ml for serotypes III and Ia, respectively, com-
ared to infants whose mothers had antibody levels ≥2 g/ml [26].
nother analysis yielded a threshold of 1 g/ml for these STs [27]
hile other studies have recommended much higher thresholds
28]. There has been considerable controversy regarding the appro-
riateness of the different ELISA methods used [29]. In general, the
ifferent methods used and the absence of reference ranges have
onfounded the interpretation of antibody studies and highlight an
rgent need for standardization.
In a longitudinal study of natural antibody and colonization,
hresholds of ≥3 g/ml for prevention of colonization with GBS
T1a and III and of 1 g/ml for STV were proposed [30]. This sug-
ests that prevention of colonization may  be another potential and
chievable beneﬁt of maternal vaccination as colonization is a pre-
equisite for EOD.
Functional assays have also been widely used and are based
n opsonophagocytosis, in which vaccine–induced antibodies pro-
ote killing of GBS by polymorphonuclear leukocytes in the
resence of complement. Again, standardization of methods is
eeded in order to facilitate the evaluation and comparison of pre-
linical and early stage clinical candidates using such assays prior
o their advancement to late stage clinical testing.
Further prospective studies in diverse settings are still required
o conﬁrm/establish protective levels for the common STs (in addi-
ion to STIa, III) for EOD as well as for LOD using standardized
ethods. Because IgG capsular antibodies are unlikely to be the
nly determinant of protection, measures of functional antibody
re also required. These studies could contribute to the licensure
athway of a GBS vaccine without needing to undertake large-scale
fﬁcacy trials in pregnant women.
Should efﬁcacy trials in pregnant women proceed, the main end-
oints would include the impact of vaccine against both EOD and
OD, culture proven and ideally, culture negative (clinical sepsis);
s well as on maternal disease. Impact (and timing of the impact)
f vaccine on GBS colonization (including density and the impact
n non-vaccine ST) at delivery, on vertical transmission, on infant
olonization and on persistence of antibody duration. Impact on
olonization could also serve as a surrogate endpoint for vaccine tri-
ls. Finally, an assessment of the impact of vaccine on prematurity,
irth asphyxia and stillbirths is also desirable, where possible [31].. Status of vaccine R&D activities
In the 1970s and 1980s human trials with plain cap-
ular polysaccharide vaccines, including in pregnant women(STIII), demonstrated them to be well tolerated but modestly
immunogenic. Vaccination was generally well tolerated. Better
immunogenicity was  then shown with conjugate vaccines. Con-
jugate vaccines were also shown to have efﬁcacy in animal models.
Experimental conjugates were subsequently constructed with CPS
of GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII. Each GBS conju-
gate induced high levels of protective antibodies in animals and
was shown to be more immunogenic than the unconjugated CPS.
Monovalent conjugate vaccines incorporating each of the ﬁve major
capsular polysaccharides of GBS have now been evaluated in phase
1 and 2 trials and in one study a bivalent conjugate vaccine was
assessed (reviewed in [32]).
All published studies have used conjugate vaccines without an
adjuvant, with one exception. In this study adsorption of GBS type
III CPS-tetanus toxoid (III-TT) conjugate vaccine to alum did not
improve the immune response in healthy adult recipients [33]. A
limited number of studies have evaluated the duration of protection
following immunization. In one study the duration of functional
activity following a GBS conjugate vaccine was evaluated among
healthy adult responders and showed substantial functional activ-
ity at 18 months to 2 years post-immunization [34].
Only one pregnancy trial with a III tetanus toxoid conjugate has
been published. A total of 20 women  in the USA received the vac-
cine while ten women received a saline control vaccine. The GBS
conjugate vaccine was well tolerated, GBS III-speciﬁc IgG rose from
0.18 g/ml before vaccination to 9.76 g/ml at delivery, showed
excellent transplacental transfer of antibody (cord/maternal ratio:
0.8) and elevated concentrations of antibody persisted in the
infants up to 2 months of age. Infant sera promoted signiﬁcant
opsonophagocytic killing of type III GBS in vitro. All infants were
born at term and were healthy through to at least 6 months of age.
Efﬁcient transplacental transfer of tetanus IgG was also reported,
raising the possibility that such conjugates may also offer protec-
tion against neonatal tetanus [17].
Phase I and II trials of a trivalent GBS vaccine (CRM197-
conjugated capsular polysaccharides of GBS serotypes Ia, Ib and
III) have been conducted in >600 non-pregnant and >500 pregnant
women in four countries. These have been designed to assess
optimal dose, need for adjuvant, immunogenicity in pregnant
women (including HIV-infected), placental transfer and persistence
in babies. The trivalent vaccine appeared to be well toler-
ated and immunogenic (results presented on clinicaltrials.gov:
NCT01193920, NCT01446289, NCT02046148).
Other vaccine targets include conserved proteins. A number of
groups have identiﬁed different surface proteins that are both rep-
resented on the surface of all strains and serotypes of the bacterium
and able to induce opsonically active antibodies. There are a num-
ber of obvious advantages with such an approach but until very
recently none had entered clinical trials in humans. MinervaX, a
privately held Danish biotech company, has recently initiated a
Phase I clinical trial with a protein-only vaccine based on a fusion
of two  immunogenic and protective protein domains from selected
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urface proteins of GBS (N-terminals of AlphaC and Rib) [35,36].
hese proteins appear to have a broad distribution among GBS
solates.
Using a reverse vaccinology approach, investigators from
ovartis were able to show that a combination of selected surface-
xposed proteins might become the basis of a universal GBS
accine. These protective antigens included proteins subsequently
ound to constitute pilus-like structures and capable of eliciting
igh titres of opsonophagocytic antibodies that protect mice in
oth active and passive immunization models [37]. Clinical trials
n humans have not yet commenced.
. Likelihood for ﬁnancing
The relatively well-characterized incidence of GBS in high
ncome countries provides the market incentive for development of
 vaccine, and historically NIH, and now large pharmaceutical com-
anies, have supported costly clinical studies. This trend is likely
o continue until a clear regulatory pathway has been established
or vaccine approval in LMICs, and it is established that candidates
urrently in development are appropriate for LMIC populations.
wo cost-effectiveness studies have recently been undertaken in
outh Africa and the USA. In the US-based study, the cost/QALY
$91,321) for a trivalent GBS vaccine was found to be compara-
le to other ACIP-recommended vaccines [38]. In the South African
tudy, maternal GBS vaccination was found to be very cost effective
er WHO  guidelines at prices up to $30/dose [12]. These studies, in
ddition to more comprehensive data on the burden of disease in
MICs will likely increase awareness of the potential for vaccine
mpact, and in turn, increase the likelihood for ﬁnancing.
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